What is Essenlix?
Essenlix Corporation is a five-year-old startup operating at the forefront of digital health, specializing in the development, manufacturing, and provision of mobile instant health test solutions. The company's iMOST platform is recognized globally for delivering accurate, reliable, and decentralized personal mobile health testing. Utilizing a single drop of body fluid and a handheld device connected to a mobile phone, Essenlix provides test results in approximately 60 seconds, making health monitoring accessible anywhere, anytime, and by anyone. The technological foundation of the iMOST platform includes the Intelligent Fault Tolerant paradigm for result accuracy under varied conditions, the QMAX universal All-In-One sample holder, intelligent nanostructures, and nano-enabled AI/machine learning (NEAM) integrated with advanced biology. This comprehensive approach positions Essenlix as a leader in bridging personal health, remote monitoring, and e-health services.
How much funding has Essenlix raised?
Essenlix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
What's next for Essenlix?
The substantial backing, particularly the recent major strategic investment, signals a pivotal growth phase for Essenlix. This capital infusion is likely to accelerate the company's expansion into new markets, further development of its iMOST platform, and scaling of its manufacturing and distribution capabilities. Essenlix's focus on decentralized and accessible health testing aligns with global trends towards preventative care and remote patient monitoring, suggesting a strong trajectory for future innovation and market penetration. The company's commitment to technological advancement, particularly in AI and nanostructures, positions it to address unmet needs in clinical and personal health diagnostics.
See full Essenlix company page
